Imatinib Plasma Monitoring-Guided Dose Modification for Managing Imatinib-Related Toxicities in Gastrointestinal Stromal Tumor Patients

Imatinib, the first-line treatment in patients with advanced gastrointestinal stromal tumors (GIST), is generally well tolerated, although some patients have difficulty tolerating the standard dose of 400 mg/day. Adjusting imatinib dosage by plasma level monitoring may facilitate management of patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Shinkyo, Ryu, Min-Hee, Yoo, Changhoon, Beck, Mo Youl, Ryoo, Baek-Yeol, Kang, Yoon-Koo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3744717/
https://www.ncbi.nlm.nih.gov/pubmed/23960456
http://dx.doi.org/10.3346/jkms.2013.28.8.1248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3744717/
https://www.ncbi.nlm.nih.gov/pubmed/23960456
http://dx.doi.org/10.3346/jkms.2013.28.8.1248

Ejemplares similares